HCP (HCP) Upgraded by ValuEngine to Sell

HCP (NYSE:HCP) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Tuesday.

HCP has been the topic of several other research reports. Wells Fargo & Co reduced their price objective on HCP from $31.00 to $27.00 and set a “market perform” rating on the stock in a report on Tuesday, March 20th. Morgan Stanley reduced their price objective on HCP from $28.00 to $23.50 and set an “equal weight” rating on the stock in a report on Thursday, June 14th. Bank of America raised HCP from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $22.63 to $25.00 in a report on Thursday, March 8th. Raymond James downgraded HCP from an “outperform” rating to a “market perform” rating in a report on Monday, May 21st. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $25.00 price objective on shares of HCP in a report on Thursday, May 3rd. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. HCP has a consensus rating of “Hold” and a consensus price target of $25.88.

Shares of HCP traded up $0.15, hitting $25.12, on Tuesday, according to Marketbeat. The company’s stock had a trading volume of 4,039,086 shares, compared to its average volume of 3,912,170. The company has a market capitalization of $11.66 billion, a P/E ratio of 12.88, a PEG ratio of 4.56 and a beta of 0.28. The company has a debt-to-equity ratio of 1.25, a current ratio of 0.15 and a quick ratio of 0.15. HCP has a fifty-two week low of $21.48 and a fifty-two week high of $33.43.

HCP (NYSE:HCP) last posted its quarterly earnings data on Thursday, May 3rd. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.38). HCP had a negative return on equity of 0.13% and a negative net margin of 0.41%. The firm had revenue of $479.20 million for the quarter, compared to analyst estimates of $452.86 million. During the same period in the prior year, the company posted $0.51 EPS. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. sell-side analysts anticipate that HCP will post 1.81 EPS for the current fiscal year.

In other HCP news, Director R Kent Griffin, Jr. bought 21,100 shares of the company’s stock in a transaction on Monday, May 14th. The stock was bought at an average price of $23.80 per share, for a total transaction of $502,180.00. Following the transaction, the director now owns 30,575 shares of the company’s stock, valued at approximately $727,685. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.14% of the company’s stock.

Several institutional investors have recently modified their holdings of HCP. Centersquare Investment Management LLC bought a new stake in shares of HCP during the 1st quarter valued at $176,082,000. Brookfield Asset Management Inc. bought a new stake in shares of HCP during the 4th quarter valued at $150,605,000. Resolution Capital Ltd bought a new stake in shares of HCP during the 1st quarter valued at $69,042,000. Renaissance Technologies LLC bought a new stake in shares of HCP during the 4th quarter valued at $39,900,000. Finally, Russell Investments Group Ltd. increased its position in shares of HCP by 108.6% in the 1st quarter. Russell Investments Group Ltd. now owns 2,762,845 shares of the real estate investment trust’s stock valued at $64,203,000 after buying an additional 1,438,692 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

About HCP

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests primarily in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply